Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I SAD Study of Apramycin in Healthy Adults
NCT04105205Phase 1Completed
- Sponsor
- Juvabis AG
- Start
- Sep 2019
- Primary completion
- Jul 2020
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of apramycin in gram-negative bacterial infections, sponsored by Juvabis AG. Primary endpoints: Type and incidence of treatment-emergent adverse events at 2 weeks, Type and incidence of TEAEs related to auditory and vestibular function tests at 3 months and 5 more. Started Sep 2019; status: completed.
02
Drugs
apramycin
03
Conditions
gram-negative bacterial infections
Beyond the preview
Go deeper on NCT04105205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04105205.